You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The increased revenues were driven in part by increased sales of Sofia immunoassay products and new products.
A number of firms now have FDA-approved Group A Strep assays, but end users may be hesitant to adopt them until Infectious Disease Society of America guidelines are updated.
The investment firm has added the three companies to its US Life Science Tools & Diagnostics coverage while upping Hologic to an Equal Weight rating.
Sales of Sofia rapid immunoassay platforms and diagnostic kits led the increase in revenues.
Solana leverages the helicase-dependent amplification technology that also underpins Quidel's AmpliVue molecular technology.
This is the first update to the guidelines since 2010, and the agency specifically calls out two of the three FDA-cleared Trichomonas NAATs.
The number of decliners in the GenomeWeb Index in April outpaced the gainers 24 to seven amid softness in the broader biotech market.
The presentations were part of a Quidel-sponsored workshop and poster sessions at the Clinical Virology Symposium in Daytona Beach, Fla.
New product revenues more than doubled year over year, while infectious disease test revenues grew 35 percent.
The trichomonas assay is Quidel's sixth assay running on the AmpliVue handheld molecular diagnostic device that has been cleared by the FDA.
Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.
An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.
Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.
In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.